These data outlined the fact that the reduced expression of BACH2 in malignant T cells confers oncogenic properties at least partly by de-repressing CD28 and CD40LG, thus promoting T-ALL proliferation and progression. This evidence concerns the gene CD28 and acute lymphoblastic leukemia.